Stockscreener 앱 받기
2.85
0.35%
-0.010
시간 외 거래:
2.85
전일 마감가:
$2.86
열려 있는:
$2.92
하루 거래량:
102.84K
Relative Volume:
0.76
시가총액:
$205.47M
수익:
$5.15M
순이익/손실:
$-65.35M
주가수익비율:
-2.1111
EPS:
-1.35
순현금흐름:
$-20.85M
1주 성능:
+9.62%
1개월 성능:
+35.07%
6개월 성능:
+83.87%
1년 성능:
+39.02%
1일 변동 폭
$2.7823
$2.95
1주일 범위
$2.56
$2.95
52주 변동 폭
$1.10
$3.24
Cellectis Adr Stock (CLLS) Company Profile
CLLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
2.85 | 286.93M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2022-05-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Robert W. Baird | Outperform |
| 2020-03-06 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-10-30 | 재개 | Guggenheim | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-05-24 | 재개 | Citigroup | Neutral |
| 2019-03-14 | 개시 | William Blair | Outperform |
| 2018-12-19 | 개시 | Goldman | Neutral |
| 2018-07-16 | 개시 | Barclays | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2017-09-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2017-09-05 | 재확인 | Wells Fargo | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-02-28 | 개시 | Wells Fargo | Outperform |
| 2016-04-05 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 개시 | BofA/Merrill | Buy |
| 2015-04-20 | 개시 | Jefferies | Buy |
| 2015-04-20 | 개시 | Piper Jaffray | Overweight |
모두보기
Cellectis Adr 주식(CLLS)의 최신 뉴스
Earnings call transcript: Cellectis Q2 2025 earnings miss drives stock down 13% - Investing.com
Cellectis earnings missed by $0.02, revenue topped estimates - Investing.com India
Cellectis earnings missed by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
European Stocks Dip As US Holders Turn Cautious - Finimize
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
European ADRs Inch Higher As Drugmakers Shine - Finimize
Cellectis shares surge 66% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
European Stocks Falter On Wall Street As ADR Index Drops - Finimize
European Equities Slip While Biopharma Stocks Shine - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com
Cellectis S.A. announces board change and meeting By Investing.com - Investing.com India
Cellectis S.A. announces board change and meeting - Investing.com
European Equities See Growth In US Trade - Finimize
Cellectis earnings beat by $0.07, revenue topped estimates - Investing.com
Cellectis earnings beat by $0.06, revenue topped estimates - Investing.com India
Cellectis Charts Course For 2025 With Boost From AstraZeneca Deal - Barchart.com
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Cellectis stock touches 52-week low at $1.14 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
Cellectis’s SWOT analysis: biotech firm’s stock faces CAR T challenges - Investing.com
Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% By Investing.com - Investing.com South Africa
Cellectis stock touches 52-week low at $1.2 amid market challenges - Investing.com India
Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% - Investing.com India
What Recent Market Trends Mean for Cosan S.A ADR’s (CSAN) Stock - The News Heater
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Cellectis Adr (CLLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):